NHS London Region Framework for Branded Medicines (Tranche A) Awarded to Multiple Suppliers

About

NHS England awarded a contract to AbbVie Ltd, Accord UK Ltd, Allergan Ltd, Amgen Ltd, Biogen Ltd., Celltrion Healthcare United Kingdom Limited, ELI LILLY & COMPANY LIMITED, Ferring Pharmaceuticals Limited, Gilead Sciences, Ipsen Limited, and Janssen for the supply of branded medicines under the NHS London Region Framework, Tranche A.

The framework covers cytokine modulators and other products, as well as Dolutegravir/Lamivudine, with contract values totaling £191,062,951.

The agreement includes multiple tranches with varying durations: London Tranche A from 1 September 2020 to 31 August 2022 (with an option to extend up to 24 months), London Annual Tranche for cytokine modulators from 1 September 2020 to 31 August 2021 (with an option to extend up to 12 months), and Dolutegravir/Lamivudine supply across North of England (1 September 2020 to 28 February 2021), South of England (1 September 2020 to 31 August 2021), and Midlands & East (1 September 2020 to 28 February 2022), all with extension options up to 24 months.